Cargando…
Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a heterogeneous disease with a high relapse rate. Cytokine receptor targeted therapies are therapeutically attractive but are subject to resistance-conferring mutations. Likewise, targeting downstream signaling pathways has been difficult. Recent success in the develo...
Autores principales: | Wang, Zhengqi, Mi, Tian, Bradley, Heath L., Metts, Jonathan, Sabnis, Himalee, Zhu, Wandi, Arbiser, Jack, Bunting, Kevin D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232307/ https://www.ncbi.nlm.nih.gov/pubmed/34203664 http://dx.doi.org/10.3390/antiox10060956 |
Ejemplares similares
-
Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells
por: Metts, Jonathan, et al.
Publicado: (2017) -
Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia
por: Laidlaw, Kamilla M.E., et al.
Publicado: (2016) -
Capillary nano-immunoassay for Akt 1/2/3 and 4EBP1 phosphorylation in acute myeloid leukemia
por: Sabnis, Himalee, et al.
Publicado: (2014) -
Liposome-Imipramine Blue Inhibits Sonic Hedgehog Medulloblastoma In Vivo
por: MacDonald, Tobey J., et al.
Publicado: (2021) -
Acute Myeloid Leukemia in an Infant with t(8;19)(p11.2;q13) Translocation: Case Report and a Review of the Literature
por: Eason, Ashley C., et al.
Publicado: (2019)